DOCSLIB.ORG

Enhanced Visualization of the Root Canal Morphology Using a Chitosan- Based Endo-Radiopaque Solution

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Enhanced Visualization of the Root Canal Morphology Using a Chitosan- Based Endo-Radiopaque Solution Restor Dent Endod. 2021 Aug;46(3):e33 https://doi.org/10.5395/rde.2021.46.e33 pISSN 2234-7658·eISSN 2234-7666 Research Article Enhanced visualization of the root canal morphology using a chitosan- based endo-radiopaque solution Shashirekha Govind ,1* Amit Jena ,2 Satabdi Pattanaik ,1 Mahaprasad Anarasi ,3 Satyajit Mohapatra ,2 Vinay Shivagange 4 1Department of Conservative Dentistry and Endodontics, Institute of Dental Sciences, Siksha ‘O’ Anusandhan Deemed to be University, Odisha, India 2Department of Conservative Dentistry and Endodontics, Sriram Chandra Bhanja Dental College & Hospital, Utkal University, Odisha, India 3Department of Conservative Dentistry and Endodontics, Hi-Tech Dental College & Hospital, Utkal University, Odisha, India 4Adult Restorative Dentistry - Endodontics, Oman Dental College, University Complutense of Madrid, Oman, Sultanate of Oman Received: Aug 26, 2020 ABSTRACT Revised: Dec 3, 2020 Accepted: Dec 9, 2020 Objectives: This study aimed to investigate the efficacy of ionic and non-ionic-based contrast Govind S, Jena A, Pattanaik S, Anarasi M, media (in vitro study) and the combinatorial effect of chitosan-based endo-radiopaque Mohapatra S, Shivagange V solution (CERS) (in vivo study) for visualization of the root canal anatomy. *Correspondence to Materials and Methods: In vitro study (120 teeth): The root canal of maxillary premolars Shashirekha Govind, BDS, MDS and molars (in vitro group 1 and 2 respectively, n = 60 each) were analyzed using 4 different Professor, Department of Conservative contrast media (subgroups: Omnipaque 350, Iopamidol, Xenetix 350, and Urografin 76;n = 15 Dentistry and Endodontics, Institute of Dental each) in combination with 5.25% sodium hypochlorite (NaOCl). Based on the results of the Sciences, Siksha ‘O’ Anusandhan Deemed to in vitro study, in vivo study (80 teeth) was done to compare Xenetix 350 + 5.25% NaOCl with be University, J-15, Khandagiri Marg, Dharam Vihar, Jagamara, Bhubaneswar, Odisha CERS (in vivo group 1 and 2 respectively, n = 40 each) on maxillary and mandibular premolars 751003, India. and molars. Two endodontists used radiovisiography to assess the depth of ingress and E-mail: [email protected] identify the aberrant root anatomy after access cavity preparation, and after initial cleaning and shaping of canals. Kruskal-Wallis test was used for in vitro comparison (p < 0.05), and Copyright © 2021. The Korean Academy of Conservative Dentistry Wilcoxon signed-rank test and Mann-Whitney U test for in vivo analysis (p < 0.01). This is an Open Access article distributed Results: In vitro study, Xenetix 350 + 5.25% NaOCl facilitated a significant higher visualization under the terms of the Creative Commons (p < 0.05). For in vivo study, CERS had a statistically significant depth of ingress (p < 0.01), Attribution Non-Commercial License (https:// and was efficient in identifying the aberrant root canal anatomy of premolars and molars. creativecommons.org/licenses/by-nc/4.0/) Conclusions: CERS facilitates better visualization of the root canal anatomy of human which permits unrestricted non-commercial use, distribution, and reproduction in any premolars and molars. medium, provided the original work is properly Keywords: Chitosan; Contrast media; Digital radiography; Root canal anatomy cited. Conflict of Interest No potential conflict of interest relevant to this article was reported. INTRODUCTION Author Contributions Accurate knowledge of the root canal anatomy, comprehensive assessment of radiograph Conceptualization: Govind S, Jena A. Data images, proper access to the canal orifices, thorough chemo-mechanical instrumentation, curation: Govind S, Anarasi M, Mohapatra S. Formal analysis: Govind S, Jena A, and 3-dimensional (3D) obturation is essential for a successful root canal therapy [1]. The Shivagange V. Funding acquisition: Govind genetic and ethnic variations in the root canal anatomy are fairly common, and they have https://rde.ac 1/12 Radiopaque solution for root canal system S, Jena A, Pattanaik S. Investigation: Govind been extensively discussed [2]. Thus, the internal root canal anatomy must be determined as S, Pattanaik S, Mohapatra S. Methodology: it is used as a basis for the course of endodontic therapy [3]. Govind S, Jena A, Pattanaik S, Anarasi M. Project administration: Govind S, Anarasi M, Mohapatra S. Resources: Govind S, Jena A, Conventional radiography is an indispensable tool for rapid chair-side visualization of the Anarasi M, Shivagange V. Software: Govind root canal anatomy, but 3D visualization is not achieved. Thus, methods that can enhance S, Jena A. Supervision: Govind S, Jena A. visualization are required. Barker et al. [4] first attempted to use an endogram to enhance Validation: Jena A, Mohapatra S, Anarasi M. the radiographic visualization of the root canals using contrast media but, the toxic lead- Visualization: Govind S, Jena A, Shivagange based elastomeric contrast media was difficult to remove from the root canals. Water-soluble S. Writing - original draft: Govind S, Jena A, contrast agents have been used with varying degrees of success [5,6]. Contrast media can Pattanaik S. Writing - review & editing: Govind S, Jena A, Shivagange V. be categorized into the ionic type (monomers: diatrizoic acid, iodic acid, and ioglicic acid and dimers: ioxaglic acid and iocarmic acid) and the non-ionic type (monomers: iohexol, ORCID iDs iopamidol, iobitridol, ioversol, iopromide, and iopentol and dimers: iotrol, iotrolan, and Shashirekha Govind iodixanol). The non-ionic type has lower osmolality and reduced chemotoxic effects and is https://orcid.org/0000-0003-4992-3087 Amit Jena better tolerated and less viscous than the ionic type [7]. https://orcid.org/0000-0002-4522-6519 Satabdi Pattanaik The Ruddle's solution is an iodinated ionic contrast media containing 5% sodium https://orcid.org/0000-0003-2686-9161 hypochlorite (NaOCl), 17% ethylenediaminetetraacetic acid (EDTA), and Hypaque (GE Mahaprasad Anarasi Healthcare, Chicago, IL, USA). NaOCl dissolves organic tissues and, enhances the ingress https://orcid.org/0000-0003-2270-7499 Satyajit Mohapatra of the radiopaque dye molecules into the root canal system. However, it should not be https://orcid.org/0000-0002-9461-9028 introduced forcefully [8]. Vinay Shivagange https://orcid.org/0000-0001-6372-0193 Chitosan is a natural polysaccharide prepared via the deacetylation of chitin and obtained from the shells of the crustaceans. It is an effective chelating agent similar to EDTA and has an antimicrobial property that prevents the growth of microorganisms in the root canal system [9-11]. Injectable radiopaque chitosan-based hydrogels have been used in endovascular therapies as sclerosing embolizing agents for the treatment of endoleaks and endovascular aneurysm repair [12,13]. Our research team formulated a chitosan-based endo- radiopaque solution (CERS), which was granted Indian patent [14]. Thus, the current study aimed to perform an in vitro comparison of 4 different contrast media introduced into the maxillary premolars and molars and in vivo comparison between Xenetix 350 + 5.25% NaOCl and CERS was conducted to visualize the root canal anatomy of the maxillary and mandibular premolars and molars. MATERIALS AND METHODS Chemicals The following chemicals were used in the experiment: Omnipaque 350 (non-ionic; GE Healthcare, Bengaluru, India), Iopamidol (non-ionic; Bracco Diagnostic Inc., Milan, Italy), Xenetix 350 (non-ionic; Guerbet, Hong Kong), Urografin 76 (ionic; Bayer, Madrid, Spain), chitosan (I-chess, Mumbai, India), and CERS, which is a mixture of 3% chitosan, iobitridol, and 100% acetone alcohol [14]. Sample size calculation The study was approved by the ethics committee of Siksha ‘O’ Anusandhan (Deemed to be University), Odisha, India (reference No. DMR/IMS-SH/SOA/16029). In vitro study was conducted over a period of 4 months (July 2016–October 2016) and the in vivo study was carried out during the period Jan 2017–March 2019 according to the STROBE statement (http://www.strobe-statement.org). The sample size was determined based on the results https://rde.ac https://doi.org/10.5395/rde.2021.46.e33 2/12 Radiopaque solution for root canal system from previous studies using G* power software, version 3.1.9 (available at http://www. gpower.hhu.de/en.html) [7,15]. With the level of significance and the power of test set at 5% and 80% respectively, the individual group sample size for in vitro was n = 60 (total 120 teeth) and for in vivo was n = 40 (total 80 teeth). In vitro experiment 1. Sample collection and preparation Extracted human maxillary premolars (group 1, n = 60) and molars (group 2, n = 60) with intact roots and mature apices were collected from the department of oral surgery according to the university guidelines. After extraction, the teeth were immersed in 5.25% NaOCl solution (Prime Dental Products Pvt Ltd., Thane, India) for 30 minutes to remove soft tissue remnants and stored in 0.2%thymol solution until use. The teeth in each group were divided (software: www.randomizer.org) into 4 subgroups (n = 15 each) according to the contrast media used (a) Omnipaque 350, (b) Xenetix 350, (c) Iopamidol, and (d) Urografin 76. Subsequently, the teeth were mounted on polyvinyl siloxane putty (President, Coltene/ Whaledent AG, Altstätten, Switzerland), and radiography in bucco-lingual and mesio-distal plane was performed using the digital radiovisiography (RVG) (CDR, FONA, Assago, Italy) and x-ray unit (X-Mind DC, Acteon, Italy) operating at 7 mA and 70 kv for 0.1 second.
Load more

Recommended publications
  • Wo 2009/081169 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 2 July 2009 (02.07.2009) WO 2009/081169 A2 (51) International Patent Classification: KJELLSON, Fred [SE/SE]; IoPharma Technologies AB, A61K 49/04 (2006.01) Ideon Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE). KLAVENESS, J o [NO/SE]; IoPharma Technologies (21) International Application Number: AB, Ideon Science Park, Ole Romers Vag 12, SE-223 70 PCT/GB2008/004268 Lund (SE). (22) International Filing Date: (74) Agent: KIDD, Sara; Frank B. Dehn 6 Co., St. Bride's 22 December 2008 (22.12.2008) House, 10 Salisbury Square, London EC4Y 8ID (GB). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (30) Priority Data: EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, 0725070.7 21 December 2007 (21.12.2007) GB IL, IN, IS, IP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicant (for all designated States except US): IO- LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, PHARMA TECHNOLOGIES AB [SE/SE]; Ideon MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE).
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,026,285 B2 Bezwada (45) Date of Patent: Sep
    US008O26285B2 (12) United States Patent (10) Patent No.: US 8,026,285 B2 BeZWada (45) Date of Patent: Sep. 27, 2011 (54) CONTROL RELEASE OF BIOLOGICALLY 6,955,827 B2 10/2005 Barabolak ACTIVE COMPOUNDS FROM 2002/0028229 A1 3/2002 Lezdey 2002fO169275 A1 11/2002 Matsuda MULT-ARMED OLGOMERS 2003/O158598 A1 8, 2003 Ashton et al. 2003/0216307 A1 11/2003 Kohn (75) Inventor: Rao S. Bezwada, Hillsborough, NJ (US) 2003/0232091 A1 12/2003 Shefer 2004/0096476 A1 5, 2004 Uhrich (73) Assignee: Bezwada Biomedical, LLC, 2004/01 17007 A1 6/2004 Whitbourne 2004/O185250 A1 9, 2004 John Hillsborough, NJ (US) 2005/0048121 A1 3, 2005 East 2005/OO74493 A1 4/2005 Mehta (*) Notice: Subject to any disclaimer, the term of this 2005/OO953OO A1 5/2005 Wynn patent is extended or adjusted under 35 2005, 0112171 A1 5/2005 Tang U.S.C. 154(b) by 423 days. 2005/O152958 A1 7/2005 Cordes 2005/0238689 A1 10/2005 Carpenter 2006, OO13851 A1 1/2006 Giroux (21) Appl. No.: 12/203,761 2006/0091034 A1 5, 2006 Scalzo 2006/0172983 A1 8, 2006 Bezwada (22) Filed: Sep. 3, 2008 2006,0188547 A1 8, 2006 Bezwada 2007,025 1831 A1 11/2007 Kaczur (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2009/0076174 A1 Mar. 19, 2009 EP OO99.177 1, 1984 EP 146.0089 9, 2004 Related U.S. Application Data WO WO9638528 12/1996 WO WO 2004/008101 1, 2004 (60) Provisional application No. 60/969,787, filed on Sep. WO WO 2006/052790 5, 2006 4, 2007.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • CUSTOMS TARIFF - SCHEDULE 99 - I
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2016 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • WO 2008/144399 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 27 November 2008 (27.11.2008) PCT WO 2008/144399 Al (51) International Patent Classification: (74) Agents: POWERS, Jeffrey, B. et al; Bausch & Lomb C07D 403/12 (2006.01) A61K 31/498 (2006.01) Incorporated, One Bausch & Lomb Place, Rochester, NY C07D 498/04 (2006.01) A61P 27/06 (2006.01) 14604-2701 (US). (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US2008/063719 AO, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (22) International Filing Date: 15 May 2008 (15.05.2008) EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, (25) Filing Language: English LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, (26) Publication Language: English PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: ZA, ZM, ZW 60/938,766 18 May 2007 (18.05.2007) US (84) Designated States (unless otherwise indicated, for every (71) Applicant (for all designated States except US): BAUSCH kind of regional protection available): ARIPO (BW, GH, & LOMB INCORPORATED [US/US]; One Bausch & GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, Lomb Place, Rochester, NY 14604-2701 (US).
    [Show full text]
  • WO 2017/222911 A1 (.Pdf)
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/222911 Al 28 December 2017 (28.12.2017) W !P O PCT (51) International Patent Classification: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, C07K 14/435 (2006.01) C12N 15/11 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/US20 17/037702 Published: (22) International Filing Date: — with international search report (Art. 21(3)) 15 June 2017 (15.06.2017) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of (25) Filing Language: English amendments (Rule 48.2(h)) (26) Publication Langi English — with sequence listing part of description (Rule 5.2(a)) (30) Priority Data: 62/352,471 20 June 2016 (20.06.2016) US (71) Applicant: THE BOARD OF TRUSTEES OF THE LE- LAND STANFORD JUNIOR UNIVERSITY [US/US]; Office of the General Counsel, Building 170, 3rd Floor, Main Quad P.O. Box 20386, Stanford, California 94305-2038 (US). (72) Inventors; and (71) Applicants: CHANG, Howard, Y. [US/US]; c/o - Office of the General Counsel, Building 170, 3rd Floor, Main Quad P.O. Box 20386, Stanford, California 94305-2038 (US). CHEN, Ye, Grace [US/US]; c/o - Office of the General Counsel, Building 170, 3rd Floor, Main Quad P.O. Box 20386, Stanford, California 94305-2038 (US).
    [Show full text]
  • Pharmacologyonline 2: 701-836 (2011) Newsletter Bradu and Rossini
    Pharmacologyonline 2: 701-836 (2011) Newsletter Bradu and Rossini CONTRAST AGENTS - FULL LIST OF THE 30 IODINATED PRODUCTS FOR WHICH REPORTS HAVE BEEN SENT OVER THE FIRST 40 YEARS OF THE WHO PHARMACOVIGILANCE SYSTEM, SUBDIVIDED INTO TWO 20-YEAR PERIODS. FOURTH WHO-ITA/ITA-OMS 2010-2011 CONTRIBUTION ON THE 30 BASIC AGGREGATED WHO SYSTEM-ORGAN CLASS DISORDERS (SOCDs), AND SUSPECTED+ ADVERSE REACTIONS AND EVENT PREFERRED NAMES (SADRs+) Dan Bradu and Luigi Rossini* Servizio Nazionale collaborativo WHO-ITA/ITA-OMS, Universita’ Politecnica delle Marche e Progetto di Farmacotossicovigilanza pre-, post-marketing, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary We have examined the PR-22 2010 data set, which includes 155,164 accepted SADRs associated with 30 iodinated contrast agents in use in the Countries participating in the WHO Pharmacovigilance Programme. The SADRs encompass 40 years, from 1968 to 2010, divided into two 20 year periods (1968-1989 and 1990-2010). The data, provided by the UMC, have been analysed in the framework of the Matlab software of correlation clustering leading to an objective classification based on the 30 standard WHO-SOCDs and preferred names. As reflected in the Title the first set of analyses regarded ATC-V08A sub-classes A (9 agents; 63,578 reports), B (12; 84,105), and C (8; 7,171). These were examined 701 Pharmacologyonline 2: 701-836 (2011) Newsletter Bradu and Rossini separately, then the results of the same procedure applied to the full matrix of 30 products and ―876 non empty‖ SADRs, including ATC-V08A sub-class D (1 agent; 310 reports) were displayed in the Appendices.
    [Show full text]